Hunter and colleagues [80] proposed that, in the early stages of carcinogenesis, CLSPN is a nuclear factor-kappa B (NF-kB) target gene that helps to prevent or reduce genome instability through its role in Chk1 activation, and therefore acts as a barrier in cancer development that results from RS. The gene discussed is NFKB1; the disease is cancer.